clinical trial · NCT05833711
Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy
Immunoforge Co. Ltd.·phase2·unknown·n = 39
DermatomyositisPolymyositisIdiopathic Inflammatory MyopathiesFroniglutidePlacebo
brief summary
This is a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Froniglutide in Patients With Idiopathic Inflammatory Myopathy ("FROniGlutide Study")
started
Sep 5, 2023
primary completion
Mar 1, 2025
completion
Sep 1, 2025
last updated
Sep 13, 2023
official title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy (IIM)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol